Experimental Therapeutics, Molecular Targets, and Chemical Biology A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia

Abstract

Evasion of apoptosis is a hallmark of chronic lymphocytic leukemia (CLL), calling for new strategies to bypass resistance. Here, we provide first evidence that small-molecule X-linked inhibitor of apoptosis (XIAP) inhibitors in combination with the death receptor ligand tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) present a novel approach to trigger apoptosis in CLL, including subgroups with resistant disease or unfavorable prognosis. XIAP, cellular IAP (cIAP) 1, and cIAP2 are expressed at high levels in primary CLL samples. Proof-of-concept studies in CLL cell lines show that subtoxic concentrations of XIAP inhibitors significantly enhance TRAIL-induced apoptosis and also sensitize for CD95-mediated apoptosis. Importantly also in primary CLL samples, XIAP inhibitor acts in concert with TRAIL to trigger apoptosis in 18 of 27 (67%) cases. This XIAP inhibitor–induced and TRAIL-induced apoptosis involves caspase-3 activation and is blocked by the caspase inhibitor zVAD.fmk. The cooperative interaction of XIAP inhibitor and TRAIL is even evident in distinct subgroups of patients with poor prognostic features (i.e., with 17pdeletion, TP53mutation, chemotherapy-refractory disease, or unmutated VH genes). Interestingly, cases with unmutated VH genes were significantly more sensitive to XIAP inhibitor–induced and TRAIL-induced apoptosis compared with VH gene–mutated samples, pointing to a role of B-cell receptor signaling in apoptosis regulation. By showing that XIAP inhibitors in combination with TRAIL present a new strategy to trigger apoptosis even in resistant forms and poor prognostic subgroups of CLL, our findings have important implications for the development of apoptosis-based therapies in CLL. [Cancer Res 2009;69(23):8977–86]

6 Figures and Tables

Cite this paper

@inproceedings{Loeder2009ExperimentalTM, title={Experimental Therapeutics, Molecular Targets, and Chemical Biology A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia}, author={Sandra Loeder and Thorsten Zenz and Andrea Schnaiter and Daniel Mertens and Dirk Winkler and Hartmut Doehner and Klaus Michael Debatin and Stephan Stilgenbauer and Simone Fulda}, year={2009} }